LOGIN  |  REGISTER

Brookdale Senior Living to Present at the Barclays Global Healthcare Conference

March 01, 2023 | Last Trade: US$7.61 0.03 -0.39

NASHVILLE, Tenn., March 1, 2023 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") announced today that Lucinda "Cindy" Baier, President and Chief Executive Officer and Dawn Kussow, Executive Vice President & Chief Financial Officer will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023. 

The Brookdale fireside chat will begin at 11:15 am ET, and the live webcast can be accessed through the Company's website at www.brookdaleinvestors.com as well as by clicking here

A replay of the webcast will be available on the Company's website until April 14, 2023. 

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities.  The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities.  Through its comprehensive network, Brookdale helps to provide seniors with care and services in an environment that feels like home. The Company's expertise in healthcare, hospitality and real estate provides residents with opportunities to improve wellness, pursue passions and stay connected with friends and loved ones. Brookdale, through its affiliates, operates and manages 673 communities in 41 states as of December 31, 2022, with the ability to serve more than 60,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD.  For more information, visit www.brookdale.com or connect with Brookdale onFacebook or Twitter

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page